Pilot Interventional Study Comparing Fetomaternal Outcomes of 150 mg Versus 75 mg Aspirin Starting Between 11 and 14 Weeks of Pregnancy in Patients with High Risk of Preeclampsia: A Randomized Control Trial.
Aspirin
MAP
Preeclampsia
Uterine Doppler
Journal
Journal of obstetrics and gynaecology of India
ISSN: 0971-9202
Titre abrégé: J Obstet Gynaecol India
Pays: India
ID NLM: 0374763
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
02
04
2019
accepted:
09
09
2019
entrez:
8
2
2020
pubmed:
8
2
2020
medline:
8
2
2020
Statut:
ppublish
Résumé
Hypertensive disorders of pregnancies complicate around 5-10% of pregnancies worldwide, and together they are a member of the deadly triad along with haemorrhage and infection that contribute to a significant amount of maternal morbidity and mortality. To compare differences in the fetomaternal outcomes with the use of 150 mg aspirin versus 75 mg aspirin in pregnant women found to be at high risk of PE. This was a two-armed double-blind parallel randomized control trial conducted in the Department of Obstetrics and Gynaecology, King George's Medical University, carried over a period of 1 year. Preeclampsia occurred in 15 of 87 participants (17%) in the 75 mg aspirin group compared with 6 of 91 (6.5%) in the 150 mg aspirin group. There were a significantly higher incidence of PE, its severity and lesser period of gestation at delivery in the group given 75 mg dose compared to the group given 150 mg dose. There were significantly higher values of mean arterial pressure and uterine artery PI in women who developed preeclampsia compared to those who do not in both the groups. Foetal outcomes were observed in both the groups of women, and there was no statistically significant difference between them. This randomized trial showed that among women with singleton pregnancies who were identified by means of first-trimester screening as being at high risk of preterm preeclampsia, use of aspirin 150 mg per day started between 11 and 14 weeks till 36 weeks is a potent intervention to reduce the development of both early- and late-onset preeclampsia as compared to a dose of 75 mg per day.
Identifiants
pubmed: 32030002
doi: 10.1007/s13224-019-01277-5
pii: 1277
pmc: PMC6982625
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23-29Informations de copyright
© Federation of Obstetric & Gynecological Societies of India 2019.
Déclaration de conflit d'intérêts
Conflict of interestThere is no conflict of interest among the authors. There is no financial relationship with any organization.
Références
Ultrasound Obstet Gynecol. 2008 Aug;32(2):128-32
pubmed: 18457355
Prenat Diagn. 2010 Dec;30(12-13):1138-42
pubmed: 20936638
Hypertension. 2008 Apr;51(4):1027-33
pubmed: 18259003
Fetal Diagn Ther. 2013;33(1):16-27
pubmed: 22986844
Ultrasound Obstet Gynecol. 2007 Oct;30(5):742-9
pubmed: 17899573
Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12
pubmed: 26297382
Fetal Diagn Ther. 2014;36(4):299-304
pubmed: 25096380
BMJ. 2008 May 17;336(7653):1079-80
pubmed: 18480114
N Engl J Med. 2017 Aug 17;377(7):613-622
pubmed: 28657417
Am J Obstet Gynecol. 2005 Mar;192(3):922-3
pubmed: 15746692
Ultrasound Obstet Gynecol. 2008 Mar;31(3):310-3
pubmed: 18241089
Obstet Gynecol. 2010 Aug;116(2 Pt 1):402-14
pubmed: 20664402
Fetal Diagn Ther. 2012;31(3):141-6
pubmed: 22441437
Fetal Diagn Ther. 2012;32(3):171-8
pubmed: 22846473
Prenat Diagn. 2011 Jan;31(1):66-74
pubmed: 21210481
Lancet. 2007 May 26;369(9575):1791-1798
pubmed: 17512048
J Obstet Gynaecol Can. 2009 Nov;31(11):1022-1027
pubmed: 20175340
Obstet Gynecol Surv. 2011 Apr;66(4):225-39
pubmed: 21756405
Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):38-42
pubmed: 21440360
Am J Obstet Gynecol. 2017 Feb;216(2):110-120.e6
pubmed: 27640943
Croat Med J. 2005 Oct;46(5):826-31
pubmed: 16158479